Ardelyx, Inc.
ARDX
Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase III cliniā¦ read more
Healthcare
Biotechnology
12 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$4.95
Price-1.79%
-$0.09
1Y
Price
Market Cap
$1.223b
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.+5.3%
EBITDA Margin-0.9%
Net Profit Margin+0.2%
Free Cash Flow Margin+5.3%
EBITDA Margin-0.9%
Net Profit Margin+0.2%
Free Cash Flow MarginRevenue
$427.679m
+19.4%
1y CAGR+108.7%
3y CAGR+185.7%
5y CAGREarnings
-$58.060m
-44.5%
1y CAGR-0.7%
3y CAGR+13.9%
5y CAGREPS
-$0.24
-35.3%
1y CAGR+12.2%
3y CAGR+27.3%
5y CAGRBook Value
$148.622m
$504.507m
Assets$355.885m
Liabilities$208.264m
DebtDebt to Assets
41.3%
-7.3x
Debt to EBITDAFree Cash Flow
-$37.499m
-20.8%
1y CAGR+0.0%
3y CAGR+13.6%
5y CAGRNo items found.
Press Releases
Statements and updates from the company